Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

Lisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center and NewYork-Presbyterian, discusses health disparities among women with breast cancer.

The R2 regimen of lenalidomide plus rituximab significantly reduced the risk of disease progression or death compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to results from the pivotal phase III AUGMENT trial.

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian-Weill Cornell Medical Center, discusses darolutamide in castration-resistant prostate cancer.

Scott T. Tagawa, MD, discusses the potential of sacituzumab govitecan in advanced urothelial cancers and reflects on progress made in prostate cancer.

Manish A. Shah, MD, discusses the results of the GAMMA-1 trial and challenges that remain for patients with gastric cancer.

Allyson J. Ocean, MD, discusses the potential impact of SM-88 in the treatment of patients with advanced pancreatic cancer and highlights a platform that patients can use to stay updated on the latest research in the field.

Scott T. Tagawa, MD, MS, discusses the clinical significance of recent clinical trial data in patients with nonmetastatic prostate cancer.

Scott T. Tagawa, MD, discusses an emerging treatment modality for patients with progressive metastatic castration-resistant prostate cancer.

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses radiotherapy in the treatment of patients with prostate cancer.

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the recent progress with HER2-targeted therapy in the treatment of breast cancer.

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the role of the immune system in cancer treatment.

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses challenges in the treatment of patients with mantle cell lymphoma (MCL).

Silvia Chiara Formenti, MD, chairman, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses immunology in the breast cancer treatment landscape.

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the promise of biosimilars in breast cancer.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the BRIGHTER study in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Manish A. Shah, MD, shares insight on the challenges that remain in the treatment of esophageal and gastric cancers.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses challenges with immunotherapy in esophageal cancer.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, highlights immunotherapy for esophageal cancer.

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses CDK4 inhibition with palbociclib (Ibrance) in mantle cell lymphoma.

Selina Chen-Kiang, PhD, details the research being conducted with CDK4/6 inhibitors in mantle cell lymphoma.

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses the use of CDK 4/6 inhibitors in mantle cell lymphoma.

Koen van Besien, MD, PhD, shares his insights on challenges with bone marrow transplant and on the potential future for these technologies in a time when the landscape is undergoing many changes.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the relationship between helicobacter pylori (H. pylori) and immune response in gastric cancer.

Koen van Besien, MD, PhD, director, Stem Cell Transplant Program, professor of medicine, Weill Cornell Medical College, attending physician, NewYork-Presbyterian Hospital, discusses use of autologous stem cell transplantation in large cell lymphoma and multiple myeloma.

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses adjuvant therapy for patients with renal cell carcinoma.

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses managing side effects from immunotherapy in renal cell carcinoma (RCC).

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma.

Allyson Ocean, MD, discusses the development of novel therapeutic regimens in pancreatic cancer.

Peter Martin, MD, reflects on the MCL data presented at the 2017 ASH Annual Meeting, and shares his insight on the future of clinical trials in the disease.

Allyson Ocean, MD, medical oncologist, attending physician, Gastrointestinal Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, medical oncologist, The Jay Monahan Center for Gastrointestinal Health, associate professor of medicine, Weill Medical College of Cornell University, discusses ongoing research on high-dose intravenous (IV) vitamin C in KRAS-mutated cells.